Xtl Biopharmaceuticals (XTLB) Return on Capital Employed (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Return on Capital Employed of 11.55% for Q4 2024, up 2116.0% year-on-year from 0.52% in Q1 2024, and up 64.68% on a QoQ basis from 32.71% in Q4 2023.
Xtl Biopharmaceuticals (XTLB) Return on Capital Employed (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Return on Capital Employed for 13 consecutive years, with 11.55% the latest figure, recorded in Q4 2024.
- Quarterly Return on Capital Employed rose 2116.0% year-over-year to 11.55% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 11.55% (up 2116.0% YoY) and the FY2025 annual result came in at 42.86%, down 1924.0% from the prior year.
- Return on Capital Employed improved to 11.55% in Q4 2024 per XTLB's latest filing, from 32.71% in the prior quarter.
- Over the last five years, Return on Capital Employed for XTLB reached as high as 7.26% in Q3 2021 and fell as low as 32.71% in Q4 2023.
- A 5-year average of 12.73% and a median of 12.71% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2020 — Return on Capital Employed slumped 2992 bps — and 2021, when it jumped 3286 bps.
- Year by year, Return on Capital Employed stood at 7.11% in 2020, then sank by 123 bps to 15.85% in 2021, then declined by 4 bps to 16.48% in 2022, then slumped by 99 bps to 32.71% in 2023, then jumped by 65 bps to 11.55% in 2024.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 11.55%, 32.71%, and 16.48% for Q4 2024, Q4 2023, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -11.55% |
| Dec 31, 2023 | -32.71% |
| Mar 31, 2022 | -16.48% |
| Dec 31, 2021 | -15.85% |
| Sep 30, 2021 | 7.26% |
| Mar 31, 2021 | -13.87% |
| Dec 31, 2020 | -7.11% |
| Sep 30, 2020 | -25.60% |
| Jun 30, 2020 | -5.90% |
| Mar 31, 2020 | -5.52% |
| Dec 31, 2019 | -11.20% |
| Sep 30, 2019 | 4.32% |
| Jun 30, 2019 | -14.59% |
| Mar 31, 2019 | -11.59% |
| Dec 31, 2018 | -10.21% |
| Sep 30, 2018 | -41.12% |
| Jun 30, 2018 | -26.21% |
| Mar 31, 2018 | -11.49% |
| Dec 31, 2017 | -19.45% |
| Sep 30, 2017 | -3.47% |